Clinical trial BYON3521.001
A first-in-human dose-escalation and expansion study with the antibodydrug conjugate BYON3521 to evaluate the safety, pharmacokinetics and efficacy in patients with c-MET expressing locally advanced or metastatic solid tumours (BYON3521.001)
| Organ | Multiple |
|---|---|
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1 |
| Academic trial | Non |
| Sponsor | Byondis |
| EudraCT Identifier | 2021-003846-19 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05323045 |
| Last update |